NOTICES Week of November 16, 2012

Transcription

1 NOTICES Week of November 16, 2012 Annual Reports to OLAW due January 31, 2013 (NOT-OD ) National Institutes of Health Notice of Intent to Publish a Funding Opportunity Announcement for Bridging the Gap Between Cancer Mechanism and Population Science (U01) (NOT-CA ) Upcoming Changes to Public Access Policy Reporting Requirements and Related NIH Efforts to Enhance Compliance (NOT-OD ) National Institutes of Health Notice of Response Date Extension for Request for Information (RFI) NOT-MD Establishing Centers of Excellence on Environment and Health Disparities (NOT-MD ) National Institute on Minority Health and Health Disparities Notice of Clarification of Award Budget and Application and Submission Instructions for RFA-RM Regional Comprehensive Metabolomics Resource Cores (RCMRC) (U24) (NOT-RM ) National Institutes of Health The Common Fund/Office of Strategic Coordination REQUEST FOR APPLICATIONS Early-Stage Innovative Molecular Analysis Technology Development for Cancer Research (R21) (RFA-CA ) Application Receipt Date(s): February 20, 2013; May 20, 2013; September 20, 2013 Validation and Advanced Development of Emerging Molecular Analysis Technologies for Cancer Research (R33) (RFA-CA ) Application Receipt Date(s): February 20, 2013; May 20, 2013; September 20, 2013 Early-Stage Development of Innovative Technologies for Biospecimen Science (R21) (RFA-CA ) Application Receipt Date(s): February 20, 2013; May 20, 2013; September 20, 2013 Validation and Advanced Development of Emerging Technologies for Biospecimen Science (R33) (RFA-CA ) Application Receipt Date(s): February 20, 2013; May 20, 2013; September 20, 2013 Novel Assays for Screening the Effects of Chemical Toxicants on Cell Differentiation (SBIR [R43]) (RFA-ES ) National Institute of Environmental Health Sciences Application Receipt Date(s): February 14, 2013 U.S.-Russia Bilateral Collaborative Research Partnerships (CRP) on the Prevention and Treatment of HIV/AIDS and Co-morbidities (R21) (RFA-DA ) National Institute on Drug Abuse Application Receipt Date(s): January 15, 2013 NIMHD Transdisciplinary Collaborative Centers for Health Disparities Research [U54] (RFA-MD ) National Institute on Minority Health and Health Disparities Application Receipt Date(s): January 15, 2013 Enhancing GTEx with molecular analyses of stored biospecimens (U01) (RFA-RM ) NIH Roadmap Initiatives Application Receipt Date(s): March 28, 2013 PROGRAM ANNOUNCEMENTS AHRQ Conference Grant Program (R13) (PA ) Agency for Healthcare Research and Quality

2 Application Receipt/Submission Date(s): February 1, May 1, August 1, and November 1 annually, beginning February 1, 2013 Administrative Supplements for Research on Sex/Gender Differences (Admin Supp) (PA ) Office of Research on Women's Health John E. Fogarty International Center National Center for Complementary and Alternative Medicine Application Receipt Date(s): January 15, 2013

3 OTHER FUNDING OPPORTUNITIES 1. TITLE: Small Grants Program for Cancer Epidemiology (R03) Synopsis: This FOA encourages the submission of Small Research Grant (R03) applications for research on cancer etiology and epidemiology. The overarching goal of this FOA is to provide support for pilot projects, testing of new techniques, secondary analyses of existing data, development and validation of measurement methods, linkage of genetic polymorphisms with other variables related to cancer risk, and development of innovative projects for more comprehensive research in cancer etiology and epidemiology. Deadline(s): March 19, 2013, July 23, 2013, November 19, 2013 Andrea R. Bell (Financial/Grants Management Contact) 6120 Executive Boulevard EPS Suite 243, MSC 7150 Bethesda, MD Phone: +1 (301) Award Amount: The R03 award mechanism will be used. A project period of up to two years and a budget for direct costs of up to $50,000 per year may be requested (i.e., a maximum of $100,000 direct costs over two years). 2. TITLE: Translational Scholar Career Awards in Pharmacogenomics and Personalized Medicine (K23) Synopsis: The overall goal of the NIH Research Career Development (K) program is to help ensure that a diverse pool of highly trained scientists is available in appropriate scientific disciplines to address the Nation's biomedical, behavioral, and clinical research needs. The purpose of this Mentored Patient-Oriented Research Career Development Award (K23) is to provide salary and "protected time" to support the career development of investigators who have made a commitment to focus their research endeavors on patient-oriented research. Each Research Career Development Award must be tailored to meet the individual needs of the candidate. The Translational Scholar Awards in Pharmacogenomics and Personalized Medicine program is intended to address the scarcity of investigators cross-trained in both clinical research core competencies and modern methods required to address pharmacogenomics research problems in patient populations. Dual mentors from the Clinical and Translational Science Awards consortium and the Pharmacogenomics Research Network are required. Deadline(s): February 12, 2013, June 12, 2013, October 12, 2013 Lisa A. Moeller (Financial/Grants Management Contact) Grants Administration Branch NIGMS, NIH 45 Center Drive, MSC 6200 Bethesda, MD Phone: +1 (301) /TTY +1 (301) Fax: +1 (301) moellerl@mail.nih.gov Award Amount: This funding opportunity will use the NIH Research Career Development Award (K23) mechanism. 3. TITLE: Validation of Molecular Diagnostics to Predict Patient Outcomes Using Specimens from Multi-Site Cancer Trials (R21)

4 Synopsis: This FOA encourages the submission of Exploratory/Developmental Research Project Grant (R21) applications from institutions and organizations to validate the clinical utility of new molecular diagnostics for determining prognosis or predicting response to therapy or toxicity for cancer. The Cancer Diagnosis Program (CDP) and the Cancer Therapy Evaluation Program (CTEP) at the NCI are cooperatively sponsoring this FOA with the purpose to transition of candidate biomarkers from initial correlative observations into diagnostics that are suitable for use in clinical trials to assess the clinical validity of a marker. This program will support pilot research projects to improve clinical decision-making in the care of cancer patients and as such will support studies that use tumor specimens linked to specific treatment and clinical outcome information. This FOA is not appropriate for molecular diagnostics discovery projects. Deadline(s): February 16, 2013, June 16, 2013, October 16, 2013 Shane Woodward, Branch Chief (Financial/Grants Management Contact) 6120 Executive Boulevard, Suite 243 Bethesda, MD Phone: +1 (301) woodwars@mail.nih.gov Award Amount: The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. 4. TITLE: Validation of Molecular Diagnostics to Predict Patient Outcomes Using Specimens from Multi-Site Cancer Trials (R01) Synopsis: This FOA encourages the submission of Research Project Grant (R01) applications from institutions and organizations to validate the clinical utility of new molecular diagnostics for determining prognosis or predicting response to therapy or toxicity for cancer. The Cancer Diagnosis Program (CDP) and the Cancer Therapy Evaluation Program (CTEP) at the NCI are cooperatively sponsoring this FOA with the purpose to transition of candidate biomarkers from initial correlative observations into diagnostics that are suitable for use in clinical trials to assess the clinical validity of a marker. This program will support research projects to improve clinical decision-making in the care of cancer patients and as such will support studies that use tumor specimens linked to specific treatment and clinical outcome information. This FOA is not appropriate for molecular diagnostics discovery projects. Deadline(s): February 5, 2013, June 5, 2013, October 5, 2013 Shane Woodward, Branch Chief (Financial/Grants Management Contact) 6120 Executive Boulevard, Suite 243 Bethesda, MD Phone: +1 (301) woodwars@mail.nih.gov Award Amount: Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum period is 5 years. 5. TITLE: Biomechanisms of Peripheral Nerve Damage by Anti-Cancer Therapy (R01) Synopsis: The purpose of this FOA is to encourage basic biologic research on damage to the peripheral nervous system instigated by pharmacologic cancer treatments, known as chemotherapy-induced peripheral neuropathy (CIPN). The majority of acquired peripheral neuropathy research has focused on diabetic and inherited diseases; this FOA intends to stimulate neuroscience researchers to apply their expertise from studying these other neuropathies to the injuries incurred by cancer treatments. More data is necessary to understand the mechanisms of neuronal damage and to identify the targets instrumental to CIPN initiation and maintenance. Preclinical research that focuses not only on peripheral

5 neuropathic pain but also on neurosensory symptoms such as paresthesias and peripheral anesthesias is invited. The ultimate goal of this FOA is to lead to a molecular understanding of CIPN that allows for the rational development of interventions that will treat or prevent CIPN. Deadline(s): February 5, 2013, June 5, 2013, October 5, 2013 Jacquelyn Boudjeda (Financial/Grants Management Contact) Phone: +1 (301) boudjedaj@mail.nih.gov Award Amount: The number of awards is contingent upon NIH appropriations, and the submission of a sufficient number of meritorious applications. 6. TITLE: Biomechanisms of Peripheral Nerve Damage by Anti-Cancer Therapy (R21) Synopsis: The purpose of this FOA is to encourage basic biologic research on damage to the peripheral nervous system instigated by pharmacologic cancer treatments, known as chemotherapy-induced peripheral neuropathy (CIPN). The majority of acquired peripheral neuropathy research has focused on diabetic and inherited diseases; this FOA intends to stimulate neuroscience researchers to apply their expertise from studying these other neuropathies to the injuries incurred by cancer treatments. More data is necessary to understand the mechanisms of neuronal damage and to identify the targets instrumental to CIPN initiation and maintenance. Preclinical research that focuses not only on peripheral neuropathic pain but also on neurosensory symptoms such as paresthesias and peripheral anesthesias is invited. The ultimate goal of this FOA is to lead to a molecular understanding of CIPN that allows for the rational development of interventions that will treat or prevent CIPN. Deadline(s): February 16, 2013, June 16, 2013, October 16, 2013 Jacquelyn Boudjeda (Financial/Grants Management Contact) Phone: +1 (301) boudjedaj@mail.nih.gov Award Amount: The combined budget for direct costs for the two-year project period may not exceed $275, TITLE: NCI Mentored Patient-Oriented Research Career Development Award to Promote Diversity (K23) Synopsis: The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of investigators who have made a commitment to focus their research endeavors on patientoriented cancer research (POR). The NCI's Diversity Training Branch and the Center to Reduce Cancer Health Disparities announce the availability of the "Mentored Patient-Oriented Research Award to Promote Diversity" for career development of individuals with a health professional doctoral degree from groups currently underrepresented on a national level in the biomedical, clinical, behavioral, and social sciences. The NCI recognizes a unique and compelling need to promote diversity in the patient-oriented research workforce. Deadline(s): February 12, 2013, June 12, 2013, October 12, 2013 Barbara Liesenfeld (Financial/Grants Management Contact) 6120 Executive Boulevard, EPS Room 243, MSC 7150 Bethesda, MD Phone: +1 (301) liesenfb@mail.nih.gov

6 Award Amount: $650,000. NIH will contribute up to $100,000 per year toward the salary of the career award recipient. NIH will contribute $30,000 per year toward the research development costs of the award recipient. Indirect Costs (also known as Facilities & Administrative [F&A] Costs) are reimbursed at 8% of modified total direct costs. 8. TITLE: NCI Transition Career Development Award to Promote Diversity (K22) Synopsis: The purpose of the award is to help ensure that a diverse pool of highly trained scientists are available in adequate numbers and in appropriate research areas to address the nation's biomedical, behavioral, and clinical research needs. The Diversity Training Branch (DTB), the Center to Reduce Cancer Health Disparities (CRCHD) invites applications from recipients of the NCI Mentored Career Development Award to Promote Diversity, or from advanced postdoctoral and/or newly independent research scientists representative of groups that are underrepresented in biomedical, behavioral, clinical, and/or social sciences. This award will provide protected time for recipients to develop and receive support for their initial cancer research program. In addition, this award can provide a two-year mentored experience in NCI intramural programs for interested individuals. Deadline(s): February 12, 2013, June 12, 2013, October 12, 2013 Barbara Liesenfeld (Financial/Grants Management Contact) 6120 Executive Boulevard, EPS Room 243, MSC 7150 Bethesda, MD Phone: +1 (301) liesenfb@mail.nih.gov Award Amount: $450,000. The K22 award mechanism will be used. Award budgets are composed of salary and other program-related expenses. NIH will contribute $100,000 per year toward the salary of the career award recipient. 9. TITLE: Behavioral Interventions to Address Multiple Chronic Health Conditions in Primary Care (R01) Synopsis: This FOA seeks Research Project Grant (R01) applications that propose to use a common conceptual model to develop behavioral interventions to modify health behaviors and improve health outcomes in patients with comorbid chronic diseases and health conditions. Specifically, this FOA will support research in primary care that uses a multidisease care management approach to behavioral interventions with high potential impact to improve patient-level health outcomes for individuals with three or more chronic health conditions. The proposed approach must modify behaviors using a common approach rather than administering a distinct intervention for each targeted behavior and/or condition. Diseases and health conditions can include, but are not limited to: mental health disorders (e.g., depression), diabetes, smoking, obesity, chronic pain, alcohol and substance abuse and dependence, chronic obstructive pulmonary disorder, cancer and hypertension. Deadline(s): February 5, 2013, June 5, 2013, October 5, 2013 Carol Perry (Financial/Grants Management Contact) Phone: +1 (301) perryc@mail.nih.gov Award Amount: The R01 award mechanism will be used. The award amount is unspecified. Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum is 5 years. 10. TITLE: NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K01)

7 Synopsis: The purpose of the NCI Mentored Research Scientist Development Award (K01) is to provide support and protected time (three, four, or five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Awards are not renewable and they are not transferable from one principal investigator (PI) to another. The Diversity Training Branch (DTB) of the Center to Reduce Cancer Health Disparities (CRCHD), at the, invites career development award applications (K01) from individuals representative of groups that have been shown to be underrepresented in health-related science, who have been recipients of an NIH Research Supplement to Promote Diversity Award, any Ruth L. Kirschstein National Research Service Award (individual F31/F32 or institutional T32), or can demonstrate that they have been supported in a mentored capacity within any research grant equivalent to an NIH peer-reviewed research grant (e.g., American Cancer Society [ACS] research grant). Candidates with clinical degrees (e.g., MD) may wish to consider the NCI Mentored Clinical Scientist Award to Promote Diversity Award (K08) and candidates interested in patient-oriented research may wish to consider the NCI Mentored Patient-Oriented Research to Promote Diversity Award (K23) as more appropriate alternatives relative to their stage of development and career goals. Deadline(s): February 12, 2013, June 12, 2013, October 12, 2013 Barbara Liesenfeld (Financial/Grants Management Contact) 6120 Executive Boulevard, EPS Room 243, MSC 7150 Bethesda, MD Phone: +1 (301) liesenfb@mail.nih.gov Award Amount: $650,000. NCI will contribute up to $100,000 per year toward the salary of the career award recipient. CI will contribute $30,000 per year toward the research development costs of the award recipient. 11. TITLE: Research on Ethical Issues in Biomedical, Social and Behavioral Research (R03) Synopsis: The purpose of this FOA is to support investigator-initiated Small Research Grant Award (R03) applications that propose to study high priority bioethical challenges and issues associated with the types of biomedical, social and behavioral research supported by the participating NIH Institutes/Centers. The Office of Behavioral and Social Sciences Research (OBSSR) joins this FOA as part of its efforts to promote research on the behavioral and social aspects of health and illness. However, only participating ICs will provide direct grant support under this FOA. Applications should address bioethical challenges and ethical issues relevant to the research mission area(s) of the participating NIH Institutes and Centers (ICs). The participating ICs have identified specific bioethics topics below as the highest priority for consideration. These are organized into seven categories: 1. Ethical considerations of new and emerging technologies; 2. Research study design issues 3. Issues associated with therapeutic misconception and the interface between treatment and research 4. Research involving vulnerable populations and urgent situations 5. Research with existing specimens, data, and health information 6. Dissemination and translation of research findings 7. Oversight of research Applications that address other bioethical issues directly related to these mission areas will also be considered. Deadline(s): February 16, 2013, June 16, 2013, October 16, 2013 Shane Woodward, Branch Chief (Financial/Grants Management Contact) 6120 Executive Boulevard, Suite 243 Bethesda, MD Phone: +1 (301) woodwards@mail.nih.gov

8 Award Amount: $100,000. A project period of up to two years and a budget for direct costs of up to $50,000 per year may be requested (i.e., a maximum of $100,000 direct costs over two years). 12. TITLE: Research on Ethical Issues in Biomedical, Social and Behavioral Research (R01) Synopsis: The purpose of this FOA is to support investigator-initiated Research Project Grant (R01) applications that propose to study high priority bioethical challenges and issues associated with the types of biomedical, social, and behavioral research supported by the participating NIH Institutes/Centers. The Office of Behavioral and Social Sciences Research (OBSSR) joins this FOA as part of its efforts to promote research on the behavioral and social aspects of health and illness. However, only participating ICs will provide direct grant support under this FOA. Applications should address bioethical challenges and ethical issues relevant to the research mission area(s) of the participating NIH Institutes and Centers (ICs). The participating ICs have identified specific bioethics topics below as the highest priority for consideration. These are organized into seven categories: 1. Ethical considerations of new and emerging technologies; 2. Research study design issues 3. Issues associated with therapeutic misconception and the interface between treatment and research 4. Research involving vulnerable populations and urgent situations 5. Research with existing specimens, data, and health information 6. Dissemination and translation of research findings 7. Oversight of research Applications that address other bioethical issues directly related to these mission areas will also be considered. Deadline(s): February 5, 2013, June 5, 2013, October 5, 2013 Shane Woodward, Branch Chief (Financial/Grants Management Contact) 6120 Executive Boulevard, Suite 243 Bethesda, MD Phone: +1 (301) woodwards@mail.nih.gov Award Amount: The award amount is unspecified. Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum period is 5 years. 13. TITLE: Senior Visiting Scientist Award SPONSOR: World Health Organization (WHO), International Agency for Research on Cancer (IARC) Synopsis: The IARC is offering a Senior Visiting Scientist Award for a qualified and experienced senior investigator with recent publications in international peer-reviewed scientific journals who wishes to spend from six to twelve months at the IARC working on a collaborative project in a research area related to the Agency's programmes. The major areas of activity are focused on understanding cancer etiology (including infections, nutrition, lifestyle, environment, radiation, genetics), developing strategies for cancer prevention (primary prevention, screening) and elucidating the underlying mechanisms of carcinogenesis through studies of molecular and cell biology, molecular genetics, epigenetics and molecular pathology. The Agency also has strong programmes dedicated to describing the global cancer burden and to the evaluation of carcinogenicity through its Monographs Programme. There is an emphasis on interdisciplinary work in the Agency's research activities as well as a focus on biostatistics, bioinformatics and related methodological developments. Candidates are requested to contact the relevant Scientific Groups in order to set up a collaborative project. The International Agency for Research on Cancer (IARC) is the specialized cancer Agency of the World Health Organization (WHO). Situated in Lyon, France, the IARC houses both epidemiology and laboratory Groups allowing it to fulfill its mission: to coordinate and conduct research on the causes of human cancer, to elucidate the mechanisms of carcinogenesis and to develop scientific strategies for cancer prevention and control. Deadline(s): November 30, 2012

9 Fellowship Programme International Agency for Research on Cancer 150 cours Albert-Thomas Lyon Cedex 08 France Phone: +33 (0) Fax: +33 (0) Award Amount Two Awards are available for The annual remuneration will be 48,000 Euros. The cost of travel for the Awardee, and in certain circumstances for dependants, will be met, and health insurance covered. 14. TITLE: Expertise Transfer Fellowship SPONSOR: World Health Organization (WHO), International Agency for Research on Cancer (IARC) Synopsis: The International Agency for Research on Cancer (IARC) is the specialized cancer Agency of the World Health Organization (WHO). Situated in Lyon, France, the IARC houses both epidemiology and laboratory Groups allowing it to fulfill its mission: to coordinate and conduct research on the causes of human cancer, to elucidate the mechanisms of carcinogenesis and to develop scientific strategies for cancer control. The IARC is offering an Expertise Transfer Fellowship to enable an established investigator to spend normally from six to twelve months in an appropriate host institute in a low- / medium-resource country* in order to transfer knowledge and expertise in a research area relevant for the host country and related to the Agency's programmes. The major areas of activity are focused on understanding cancer etiology (including infections, nutrition, lifestyle, environment, radiation, genetics), developing strategies for cancer prevention (primary prevention, screening) and elucidating the underlying mechanisms of carcinogenesis through studies of molecular and cell biology, molecular genetics, epigenetics and molecular pathology. The Agency also has strong programmes dedicated to describing the global cancer burden and to the evaluation of carcinogenicity through its Monographs Programme. There is an emphasis on interdisciplinary work in the Agency's research activities. Applications should include a proposed collaborative research project, specifying the link to IARC's on-going activities and a letter of support from the host lab giving details of feasibility and anticipated benefit to the receiving institute. A letter of endorsement from a research Group at IARC must also be provided. Priority will be given to projects directly linked to IARC's ongoing research programme, involving at least one contact at IARC. Deadline(s): Extended to December 31, 2012 Fellowship Programme International Agency for Research on Cancer 150 cours Albert-Thomas Lyon Cedex 08 France Phone: +33 (0) Fax: +33 (0) fel@iarc.fr Award Amount There will be an annual remuneration of up to US$70,000 which will take into account the ongoing salary of the fellow. 15. TITLE: Postdoctoral Fellowships for Training in Cancer Research SPONSOR: World Health Organization (WHO), International Agency for Research on Cancer (IARC) Synopsis: Applications for training fellowships in are invited from junior scientists wishing to complete their training in those aspects of cancer research related to the Agency's mission: to coordinate and conduct both epidemiological and laboratory research into the causes and prevention of cancer. Disciplines covered are: epidemiology (including genetic and molecular), biostatistics, bioinformatics, and areas related to mechanisms of carcinogenesis including molecular and cell biology, molecular genetics, epigenetics, and molecular pathology. There is an emphasis on interdisciplinary projects. Fellowships are tenable at the IARC in Lyon, France working in a research Group.

10 Candidates must contact the host Group of their choice at IARC before application in order to interact closely to establish a proposed programme of mutual interest. Deadline(s): November 30, 2012 Fellowship Programme International Agency for Research on Cancer 150 cours Albert-Thomas Lyon Cedex 08 France Phone: +33 (0) Fax: +33 (0) fel@iarc.fr Award Amount The fellowship is for a period of two years, the second year being subject to satisfactory appraisal. Fellowships must be taken up by November 30 of the year of award. The annual stipend is currently Euros and will be paid monthly in advance. Stipends are not considered as a substitute for any salary paid to a Fellow at home. 16. TITLE: Scholarships SPONSOR: Cancer for College TITLE: Preventative Health Flagship Project SPONSOR: CSIRO Australia TITLE: Cancer Research Grant Program SPONSOR: The Mary Kay Foundation TITLE: Medical Research Grants SPONSOR: Friends for an Earlier Breast Cancer Test TITLE: Fellowship : Winter 2013 Priority Announcements - Jean-Francois St-Denis Prize (FJF) SPONSOR: Canadian Institutes of Health Research (CIHR) esultcount=25&sort=program 21. TITLE: Bachelor's in Nursing Degree Scholarship SPONSOR: Oncology Nursing Foundation/Society TITLE: Master s Scholarships SPONSOR: Oncology Nursing Foundation/Society TITLE: Ann Olson Memorial Doctoral Scholarship SPONSOR: Oncology Nursing Foundation/Society TITLE: Doctoral Scholarships SPONSOR: Oncology Nursing Foundation/Society